Who expert committee on biological standardization

World Health Organization - Technical Report Series

Volumn , Issue 878, 1998, Pages 1-101

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; CYTOKINE; DNA VACCINE; ENDOTOXIN; FERRITIN; FOLIC ACID; RUBELLA ANTIBODY; THROMBOPLASTIN; THYROID ANTIBODY; THYROTROPIN; BIOLOGICAL PRODUCT; PERTUSSIS VACCINE;

BIOTECHNOLOGY; CONFERENCE PAPER; GOOD MANUFACTURING PRACTICE; PRACTICE GUIDELINE; STANDARDIZATION; WORLD HEALTH ORGANIZATION; ANIMAL; ARTICLE; CELL CULTURE; HUMAN; INTERNATIONAL COOPERATION; STANDARD;

ANIMALS; BIOLOGICAL PRODUCTS; CELLS, CULTURED; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; PERTUSSIS VACCINE; REFERENCE STANDARDS; VACCINES, DNA; WORLD HEALTH ORGANIZATION;

EID: 0031615886     PISSN: 05123054     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (43)

1. Van Wezel AL. Microcarrier technology - present status and prospects. Developments in biological standardization, 1984, 55:3.
2. Jacobs JP et al. Guidelines for the acceptability, management and testing of serially propagated human diploid cells for the production of live virus vaccines for use in man. Journal of biological standardization, 1981, 9:331-342.
3. Hayflick L, Plotkin S, Stevenson R. History of the acceptance of human diploid cell strains as substrates for human virus vaccine production. Developments in biological standardization, 1987, 68:9-17.
4. Grachev, V. World Health Organization attitude concerning the use of continuous cell lines as substrate for production of human virus vaccines. In: Mizrahi A, ed. Advances in biotechnological processes, Vol, 14. Viral vaccines. Wiley-Liss, 1990:37-67.
5. Acceptability of cell substrates for production of biologicals. Report of a WHO Study Group. Geneva, World Health Organization, 1987 (WHO Technical Report Series, No. 747).
6. Requirements for continuous cell lines used for biologicais production. In: WHO Expert Committee on Biological Standardization, Thirty-sixth Report. Geneva, World Health Organization, 1987, Annex 3 (WHO Technical Report Series, No, 745).
7. WHO bank of Vero cells for the production of biologicais, In; WHO Expert Committee on Biological Standardization, Fortieth Report. Geneva, World Health Organization, 1990, p. 11 (WHO Technical Report Series, No. 800).
8. Temin HM. Overview of biological effects of addition of DNA molecules to cells. Journal of medical virology, 1990, 31:13-17.
9. Kurth R. Risk potential of the chromosomal insertion of foreign DMA. Annals of the New York Academy of Sciences, 1995, 772:140-150.
10. Petricciani JC, Horaud FN. DNA, dragons, and sanity. Biologicals, 1995, 23:233-238.
11. Nichols WW et al. Potential DNA vaccine integration into host cell genome. Annals of the New York Academy of Science, 1995, 772:30-38.
12. Coffin JM. Molecular mechanisms of nucleic acid integration. Journal of medical virology, 1990, 31:43-49.
13. Petricciani JC, Regan PJ. Risk of neoplastic transformation from cellular DNA: calculations using the oncogene model. Developments in biological standardization, 1986, 68:43-49.
14. Strain AJ. The uptake and fate of DNA transfected into mammalian cells In vitro. Developments in biological standardization, 1986, 68:27-32.
15. Doehmer J. Residual cellular DNA as a potential transforming factor. Developments in biological standardization, 1986, 68:33-41.
16. Wierenga DE, Cogan J, Petriccaini JC. Administration of tumor cell chromatin to immunosuppressed and non-immunosuppressed primates. Biologicals, 1995, 23:221-224.
17. Greenwald P et al. Morbidity and mortality among recipients of blood from pre-leukemic and pre-lymphomatous donors. Cancer, 1976, 38: 324-328.
18. Fleckenstein B, Daniel MD, Hunt RD. Tumor inductions with DNA of oncogenic primate herpesviruses. Nature, 1978, 274: 57-59.
19. Duxbury M et al. DNA in plasma of human blood for transfusion. Biologicals, 1995, 23:229.
20. Nawroz H et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nature medicine, 1996, 2:1035-1037.
21. Perrin P, Morgeaux S. Inactivation of DNA by beta-propiolactone, Biologicals, 1995, 23:207.
22. Requirements for Poliomyelitis Vaccine (Inactivated). In: Requirements for Biological Substances: 1. General Requirements for Manufacturing Establishments and Control Laboratories; 2. Requirements for Poliomyelitis Vaccine (Inactivated). Report of a Study Group. Geneva, World Health Organization, 1959 (WHO Technical Report Series, No. 178).
23. Requirements for Poliomyelitis Vaccine (Inactivated). In: Requirements for Biological Substances. Manufacturing and Control Laboratories. Report of a WHO Expert Group. Geneva, World Health Organization, 1966 (WHO Technical Report Series, No, 323).
24. Hilleman M. Cells, vaccines and pursuit of precedent. Bethesda, MD, National Cancer Institute, 1968 (National Cancer Institute Monograph, No. 29).
25. Requirements for Poliomyelitis Vaccine (Oral) (Requirements for Biological Substances No. 7, revised 1989). In: WHO Expert Committee on Biological Standardization. Fortieth Report. Geneva, World Health Organization, 1990, Annex 1 (WHO Technical Report Series, No, 800).
26. Good manufacturing practices for pharmaceutical products. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No, 823).
27. Good manufacturing practices for biological products. In: WHO Expert Committee on Biological Standardization. Forty-second Report. Geneva, World Health Organization, 1992, Annex 1 (WHO Technical Report Series, No. 822).
28. Questions de santé publique liées aux encéphalopathies spongiformes chez l'animal et chez l'homme: Mémorandum d'une réunion de l'OMS. Bulletin of the World Health Organization, 1992, 70:573-582.
29. Report of a WHO Consultation on Medicinal and Other Products in Relation to Human and Animal Transmissible Spongiform Encephalopathies. Geneva, World Health Organization, 1997 (unpublished document WHO/BLG/97,2; available on request from Biologicals, World Health Organization, 1211 Geneva 27, Switzerland).
30. Requirements for Measles, Mumps and Rubella Vaccines and Combined Vaccine (Live) (Requirements for Biological Substances No. 47, 1992). In: WHO Expert Committee on Biological Standardization. Forty-fourth Report. Geneva, World Health Organization, 1994, Annex 3 (WHO Technical Report Series, No. 840).
31. General Requirements for the Sterility of Biological Substances (Requirements for Biological Substances No. 6, revised 1973). In: WHO Expert Committee on Biological Standardization. Twenty-fifth Report. Geneva, World Health Organization, 1973, Annex 4 (Technical Report Series, No. 530).
32. General Requirements for the Sterility of Biological Substances (Requirements for Biological Substances No, 6, revised 1973, amendment 1995). In: WHO Expert Committee on Biological Standardization. Forty-sixth Report. Geneva, World Health Organization, 1998, Annex 3 (WHO Technical Report Series, No, 872).
33. Requirements for the Collection, Processing and Quality Control of Blood, Blood Components and Plasma Derivatives (Requirements for Biological Substances No, 27, revised 1992). In: WHO Expert Committee on Biological Standardization. Forty-third Report. Geneva, World Health Organization, 1994, Annex 2 (WHO Technical Report Series No. 840).
34. Viral safety evaluation of biotechnology products. Geneva, International Conference on Harmonisation, 1997 (unpublished document available on request from International Conference on Harmonisation Secretariat, International Federation of Pharmaceutical Manufacturers Associations, 30 rue de St-Jean, 1211 Geneva 18, Switzerland).
35. Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology, In: WHO Expert Committee on Biological Standardization. Forty-first Report. Geneva, World Health Organization, 1991, Annex 3 (WHO Technical Report Series, No. 814).
36. Requirements for Hepatitis B Vaccines made by Recombinant DNA Techniques. In: WHO Expert Committee on Biological Standardization. Thirty-ninth Report. Geneva, World Health Organization, 1989, Annex 2 (WHO Technical Report Series, No. 786).
37. Peebles PT. An in vitro focus-induction assay for xenotropic murine leukemia virus, feline leukemia virus C, and the feline-primate viruses RD-114/CC/M-7. Virology, 1975, 67:288-291.
38. Sammerfelt MA, Weiss RA. Receptor interference groups of 20 retroviruses plating on human cells. Virology, 1990, 176:58-69.
39. Lander MR, Chattopadhyay SK. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ecotropic, amphotropic, xenotropic, and mink cell focus-forming viruses. Journal of virology, 1984, 52:695-698.
40. Hartley RH, Rowe WP. Clonal cell lines from a feral mouse embryo which lack host-range restrictions for murine leukemia viruses, Virology, 1975, 65:128-134.
41. Bassin RH et al. Normal DBA/2 mouse cells synthesize a glycoprotein which interferes with MCF virus infection, Virology, 1982, 123:139-151.
42. Bassin RH, Tuttle N, Fischinger PJ. Rapid cell culture assay technic for murine leukeamia viruses. Nature, 1971, 229:564-566.
43. Analysis of the expression construct in cells used for production of a DNA-derived protein product. Geneva, International Conference on Harmonisation, 1995 (unpublished document available on request from International Conference on Harmonisation Secretariat, International Federation of Pharmaceutical Manufacturers Associations, 30 rue de St-Jean, 1211 Geneva 18, Switzerland).